Panacea Biotec Awarded Contract to Supply Vaccine to Central Medical Services Society
Panacea Biotec Limited has secured a Letter of Award (LOA) from the Central Medical Services Society, under the Ministry of Health and Family Welfare, Government of India. The agreement concerns the supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP.The LOA, dated April 10, 2026, specifies that the company will provide the Td Vaccine in multiple tranches to the Central Medical Services Society. The supply period is slated to begin between September and October 2026 and conclude between November and December 2028.
The total value aggregated for this contract stands at INR 20.79 Crore.
Key details regarding the contract awarded to Panacea Biotec Limited are presented below:
| Particulars | Details |
|---|---|
| Entity Awarding the Order | Central Medical Services Society, Ministry of Health and Family Welfare, Government of India (CMSS) |
| Nature of Order | Supply of Td Vaccine to CMSS |
| Contract Value | INR 20.79 Crore |
| Execution Period | September / October 2026 till November / December 2028 |
| Contract Source | Domestic entity |
The transaction is categorized as a domestic order concerning the supply of Td Vaccine to CMSS. The LOA indicates that the promoter group has no interest in the awarding entity, and the contract does not fall within related party transactions.
PANACEABIO Stock Price Movement
On Friday, Panacea Biotec Limited shares edged higher to close at ₹327.15, marking a solid 1.29% gain for the session. The stock settled near the day's high amid a noticeable trading day, posting a total volume of 88,430 shares.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.